A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma - Trial NCT06235229
Access comprehensive clinical trial information for NCT06235229 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Gracell Biotechnologies Ltd. and is currently Recruiting. The study focuses on Multiple Myeloma. Target enrollment is 110 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Gracell Biotechnologies Ltd.
Timeline & Enrollment
Phase 1/2
Dec 07, 2023
Jun 01, 2026
Primary Outcome
Phase 1: Dose-limiting toxicities,Phase 2: Overall response rate
Summary
This study is a single-arm, open-lable, phase I/II study to evaluate the efficacy and safety
 of GC012F in subjects with relapsed/refractory multiple myeloma.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06235229
Non-Device Trial